市場調查報告書
商品編碼
966792

黃斑部毛細血管擴張症(MacTel):流行病學洞察(至2030年的預測)

Macular Telangiectasia (MacTel) - Epidemiology Insight - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,法國,義大利,西班牙,英國),日本)的黃斑部毛細血管擴張症(MacTel)的相關調查,流行病學及預測,各市場區隔的病例,診斷案例等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 疾病的背景和概要

  • 概要
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者的治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論性根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 流行病學方案(2017-2030)
  • 美國流行病學
  • 歐洲5國流行病學
    • 德國流行病學
    • 法國流行病學
    • 義大利流行病學
    • 西班牙流行病學
    • 英國流行病學
  • 日本流行病學

第6章 治療流程,目前治療,及醫務

  • 治療和管理
  • 治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文獻
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1067

DelveInsight's 'Macular Telangiectasia (MacTel) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Macular Telangiectasia (MacTel) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Macular Telangiectasia (MacTel) Understanding

The DelveInsight Macular Telangiectasia (MacTel) epidemiology report gives a thorough understanding of the Macular Telangiectasia (MacTel) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Macular Telangiectasia (MacTel) in the US, Europe, and Japan. The report covers the detailed information of the Macular Telangiectasia (MacTel) epidemiology scenario in seven major countries (US, EU5, and Japan).

Macular Telangiectasia (MacTel) Epidemiology Perspective by DelveInsight

The Macular Telangiectasia (MacTel) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Macular Telangiectasia (MacTel) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Macular Telangiectasia (MacTel) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Macular Telangiectasia (MacTel) Detailed Epidemiology Segmentation

The Macular Telangiectasia (MacTel) epidemiology covered in the report provides historical as well as forecasted Macular Telangiectasia (MacTel) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Macular Telangiectasia (MacTel) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Macular Telangiectasia (MacTel) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Macular Telangiectasia (MacTel) Epidemiology Report and Model provide an overview of the risk factors and global trends of Macular Telangiectasia (MacTel) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Macular Telangiectasia (MacTel) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Macular Telangiectasia (MacTel)
  • The report provides the segmentation of the Macular Telangiectasia (MacTel) epidemiology

Report Highlights:

  • 11-Year Forecast of Macular Telangiectasia (MacTel) epidemiology
  • 7MM Coverage
  • Total Cases of Macular Telangiectasia (MacTel)
  • Total Cases of Macular Telangiectasia (MacTel) according to segmentation
  • Diagnosed cases of Macular Telangiectasia (MacTel)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Macular Telangiectasia (MacTel)?
  • What are the key findings pertaining to the Macular Telangiectasia (MacTel) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Macular Telangiectasia (MacTel) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Macular Telangiectasia (MacTel)?
  • What are the currently available treatments of Macular Telangiectasia (MacTel)?

Reasons to buy:

  • The Macular Telangiectasia (MacTel) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Macular Telangiectasia (MacTel) market
  • Quantify patient populations in the global Macular Telangiectasia (MacTel) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Macular Telangiectasia (MacTel) therapeutics in each of the markets covered
  • Understand the magnitude of Macular Telangiectasia (MacTel) population by its epidemiology
  • The Macular Telangiectasia (MacTel) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Macular Telangiectasia (MacTel)

3. Macular Telangiectasia (MacTel) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Macular Telangiectasia (MacTel) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Macular Telangiectasia (MacTel) Treatment and Management
  • 6.2. Macular Telangiectasia (MacTel) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Macular Telangiectasia (MacTel) Epidemiology in 7MM (2017-2030)
  • Table 2: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Macular Telangiectasia (MacTel) Epidemiology in the United States (2017-2030)
  • Table 4: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Macular Telangiectasia (MacTel) Epidemiology in Germany (2017-2030)
  • Table 6: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Macular Telangiectasia (MacTel) Epidemiology in France (2017-2030)
  • Table 8: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Macular Telangiectasia (MacTel) Epidemiology in Italy (2017-2030)
  • Table 10: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Macular Telangiectasia (MacTel) Epidemiology in Spain (2017-2030)
  • Table 12: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Macular Telangiectasia (MacTel) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Macular Telangiectasia (MacTel) Epidemiology in Japan (2017-2030)
  • Table 16: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Macular Telangiectasia (MacTel) Epidemiology in 7MM (2017-2030)
  • Figure 2: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Macular Telangiectasia (MacTel) Epidemiology in the United States (2017-2030)
  • Figure 4: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Macular Telangiectasia (MacTel) Epidemiology in Germany (2017-2030)
  • Figure 6: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Macular Telangiectasia (MacTel) Epidemiology in France (2017-2030)
  • Figure 8: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Macular Telangiectasia (MacTel) Epidemiology in Italy (2017-2030)
  • Figure 10: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Macular Telangiectasia (MacTel) Epidemiology in Spain (2017-2030)
  • Figure 12: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Macular Telangiectasia (MacTel) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Macular Telangiectasia (MacTel) Epidemiology in Japan (2017-2030)
  • Figure 16: Macular Telangiectasia (MacTel) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report